Selective effects of somatostatin-14, -25 and -28 on in vitro insulin and glucagon secretion

Abstract
SRIF-28 [somatostatin-28 from porcine gut] and SRIF-25 [somatostatin-25 from ovine hypothalamus] are more potent than SRIF-14 [somatostatin-14] in the inhibition of insulin release, but SRIF-14 preferentially inhibits glucagon release. SRIF-28 and SRIF-25 are probably not mere biosynthetic precursors of SRIF-14 and their differential release may be physiologically important.